Wells Fargo Downgrades Tokai Pharmaceuticals (TKAI) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Tokai Pharmaceuticals Announces Clinical Update
July 26, 2016 7:00 AM EDTCompany to Discontinue Phase 3 ARMOR3-SV Trial of Galeterone in AR-V7 Positive mCRPC
Tokai to Host Conference Call Today at 8:30 AM E.T.
BOSTON--(BUSINESS WIRE)-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that it plans to discontinue the ARMOR3-SV clinical trial, the companys pivotal Phase 3 study comparing galeterone to enzalutamide in treatment-naïve metastatic castration-resistant prostate cancer (mCRPC) patients whose prostate tumors express AR-V7, following... More
